Mediar Therapeutics
Cambridge, MA, United States · Biotechnology, Health Care, Other · 49 employees
Mediar Therapeutics is pioneering a new approach to fibrosis treatment that aims to halt the disease at a different source – the myofibroblast, the key pathogenic cell in fibrosis that drives scarring, disease progression, and ultimately organ failure. Mediar was founded based on a deep understanding of the complex science underlying fibrosis progression. By combining novel targets with reliabl
Funding history
- Series SERIES B — $76.0M — Jan 2026
- Funding Round — $37.8M — Dec 2025
- Funding Round — $85.0M — Oct 2024
- Funding Round — $31.8M — Dec 2022
- Funding Round — $85.0M — Feb 2019
Recent signals
- Jan 07, 2026: Raised $76.0M in Series SERIES B
- Dec 23, 2025: Raised $37.8M
- Oct 22, 2024: Raised $85.0M
- Dec 02, 2022: Raised $31.8M
- Feb 06, 2019: Raised $85.0M
See plans & pricing → Track Mediar Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.